胰腺癌治疗的新靶点。

Novel targets for pancreatic cancer therapy.

作者信息

Philip Philip A

机构信息

Division of Hematology and Oncology, Department of Internal Medicine, Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R Street, 4-HWCRC, Detroit, MI 48201, USA.

出版信息

Surg Oncol Clin N Am. 2010 Apr;19(2):419-29. doi: 10.1016/j.soc.2009.11.012.

DOI:10.1016/j.soc.2009.11.012

PMID:20159523

Abstract

Pancreatic adenocarcinoma (PDA) is one of the cancers that is resistant to most conventional anticancer therapies. PDA-affected patients show a poor prognosis. The 5-year survival rate for PDA is 5% and has changed little over the past few decades. This has prompted extensive research to identify new agents that can be used for anticancer therapy. The only cytotoxic drug that has been approved by the Food and Drug Administration (FDA) is gemcitabine, which offers marginal benefits to patients in terms of symptom control and prolongation of life. Various strategies like targeting the epidermal growth factor receptor pathway and vascular endothelial growth factor receptor pathway have been researched upon. But these strategies have not provided promising results and none of the FDA-approved targeted agents have added any substantial clinical benefit to gemcitabine except for a marginal benefit from erlotinib. This article discusses various possible new targets and new agents for the anticancer therapy for PDA.

摘要

胰腺腺癌（PDA）是对大多数传统抗癌疗法具有抗性的癌症之一。受PDA影响的患者预后较差。PDA的5年生存率为5%，在过去几十年中变化不大。这促使人们进行广泛研究以确定可用于抗癌治疗的新药物。美国食品药品监督管理局（FDA）批准的唯一细胞毒性药物是吉西他滨，它在症状控制和延长生命方面给患者带来的益处有限。人们已经研究了各种策略，如靶向表皮生长因子受体途径和血管内皮生长因子受体途径。但这些策略并未取得令人满意的结果，除了厄洛替尼带来的些许益处外，FDA批准的靶向药物均未给吉西他滨带来任何实质性的临床益处。本文讨论了PDA抗癌治疗的各种可能的新靶点和新药物。